<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Adma Biologics Inc — News on 6ix</title>
<link>https://6ix.com/company/adma-biologics-inc</link>
<description>Latest news and press releases for Adma Biologics Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 29 Apr 2026 11:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/adma-biologics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo683542a278dffbe2df0e15ee.webp</url>
<title>Adma Biologics Inc</title>
<link>https://6ix.com/company/adma-biologics-inc</link>
</image>
<item>
<title>ADMA Biologics to Report First Quarter 2026 Financial Results on May 6, 2026</title>
<link>https://6ix.com/company/adma-biologics-inc/news/adma-biologics-to-report-first-quarter-2026-financial-results-on-may-6-2026</link>
<guid isPermaLink="true">https://6ix.com/company/adma-biologics-inc/news/adma-biologics-to-report-first-quarter-2026-financial-results-on-may-6-2026</guid>
<pubDate>Wed, 29 Apr 2026 11:00:00 GMT</pubDate>
<description>Conference Call Scheduled for May 6, 2026, at 4:30 p.m. ETRAMSEY, N.J. and BOCA RATON, Fla., April 29, 2026 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), a U.S. based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics, today announced that it will report first quarter 2026 financial results on May 6, 2026, after the U.S. financial markets close. ADMA’s management team will host a live conf</description>
</item>
<item>
<title>ADMA Biologics Issues Statement Refuting Unsubstantiated, Misleading and Inaccurate Allegations by Culper Research</title>
<link>https://6ix.com/company/adma-biologics-inc/news/adma-biologics-issues-statement-refuting-unsubstantiated-misleading-and-inaccurate-allegations-by-culper-research</link>
<guid isPermaLink="true">https://6ix.com/company/adma-biologics-inc/news/adma-biologics-issues-statement-refuting-unsubstantiated-misleading-and-inaccurate-allegations-by-culper-research</guid>
<pubDate>Fri, 27 Mar 2026 04:00:00 GMT</pubDate>
<description>Short seller’s Characterization of ASCENIV’s Competitive Position Reflects Blatant Misunderstanding of ADMA’s Business and Its Role as Late-line Therapy for</description>
</item>
<item>
<title>ADMA Biologics Addresses Misleading Short-Seller Report</title>
<link>https://6ix.com/company/adma-biologics-inc/news/adma-biologics-addresses-misleading-short-seller-report</link>
<guid isPermaLink="true">https://6ix.com/company/adma-biologics-inc/news/adma-biologics-addresses-misleading-short-seller-report</guid>
<pubDate>Wed, 25 Mar 2026 04:00:00 GMT</pubDate>
<description>RAMSEY, N.J. and BOCA RATON, Fla., March 25, 2026 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), a U.S. based, end-to-end</description>
</item>
<item>
<title>ADMA Biologics Announces $125 Million Accelerated Share Repurchase with JPMorgan as Part of a Planned $200 Million 2026 Total Share Repurchase Initiative</title>
<link>https://6ix.com/company/adma-biologics-inc/news/adma-biologics-announces-dollar125-million-accelerated-share-repurchase-with-jpmorgan-as-part-of-a-planned-dollar200-million-2026-total-share-repurchase-initiative</link>
<guid isPermaLink="true">https://6ix.com/company/adma-biologics-inc/news/adma-biologics-announces-dollar125-million-accelerated-share-repurchase-with-jpmorgan-as-part-of-a-planned-dollar200-million-2026-total-share-repurchase-initiative</guid>
<pubDate>Mon, 02 Mar 2026 05:00:00 GMT</pubDate>
<description>RAMSEY, N.J. and BOCA RATON, Fla., March 02, 2026 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), a U.S. based, end-to-end</description>
</item>
<item>
<title>ADMA Biologics Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/adma-biologics-inc/news/adma-biologics-reports-record-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update</link>
<guid isPermaLink="true">https://6ix.com/company/adma-biologics-inc/news/adma-biologics-reports-record-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update</guid>
<pubDate>Wed, 25 Feb 2026 21:05:00 GMT</pubDate>
<description>FY 2025 Total Revenue of $510 Million, Representing 20% Year-Over-Year Growth FY 2025 ASCENIV Revenue Grew to $363 Million, Representing 51% Year-Over-Year Growth FY 2025 Adjusted Net Income(1) of $161 Million, Representing 35% Year-Over-Year Growth FY 2025 Adjusted EBITDA(2) of $231 Million, Representing 40% Year-Over-Year Growth Incoming CFO Appointment Expected to Further Enhance Financial Strategy, Working Capital Execution and Capital Allocation Discipline Advancing SG-001 Pipeline Program</description>
</item>
<item>
<title>ADMA Biologics to Report Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026</title>
<link>https://6ix.com/company/adma-biologics-inc/news/adma-biologics-to-report-fourth-quarter-and-full-year-2025-financial-results-on-february-25-2026</link>
<guid isPermaLink="true">https://6ix.com/company/adma-biologics-inc/news/adma-biologics-to-report-fourth-quarter-and-full-year-2025-financial-results-on-february-25-2026</guid>
<pubDate>Wed, 18 Feb 2026 05:00:00 GMT</pubDate>
<description>Conference Call Scheduled for February 25, 2026, at 4:30 p.m. ET RAMSEY, N.J. and BOCA RATON, Fla., Feb. 18, 2026 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc.</description>
</item>
<item>
<title>ADMA Biologics Announces Preliminary Full Year 2025 Unaudited Total Revenue and Provides Business Update</title>
<link>https://6ix.com/company/adma-biologics-inc/news/adma-biologics-announces-preliminary-full-year-2025-unaudited-total-revenue-and</link>
<guid isPermaLink="true">https://6ix.com/company/adma-biologics-inc/news/adma-biologics-announces-preliminary-full-year-2025-unaudited-total-revenue-and</guid>
<pubDate>Mon, 12 Jan 2026 05:00:00 GMT</pubDate>
<description>FY 2025 Preliminary Unaudited Total Revenue of Approximately $510–511 Million Meets or Exceeds Prior Guidance Previously Provided FY 2025 Adjusted EBITDA(1)</description>
</item>
<item>
<title>ADMA Biologics to Present at the J.P. Morgan Healthcare Conference on January 12, 2026</title>
<link>https://6ix.com/company/adma-biologics-inc/news/adma-biologics-present-jp-morgan-healthcare-conference-january-12-2026-2026-01-05</link>
<guid isPermaLink="true">https://6ix.com/company/adma-biologics-inc/news/adma-biologics-present-jp-morgan-healthcare-conference-january-12-2026-2026-01-05</guid>
<pubDate>Mon, 05 Jan 2026 05:00:00 GMT</pubDate>
<description>RAMSEY, N.J. and BOCA RATON, Fla., Jan. 05, 2026 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), a U.S.-based, end-to-end</description>
</item>
<item>
<title>ADMA Biologics Announces Third Quarter 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/adma-biologics-inc/news/adma-biologics-announces-third-quarter-2025-financial-results-and-provides-business</link>
<guid isPermaLink="true">https://6ix.com/company/adma-biologics-inc/news/adma-biologics-announces-third-quarter-2025-financial-results-and-provides-business</guid>
<pubDate>Wed, 05 Nov 2025 05:00:00 GMT</pubDate>
<description>3Q 2025 Total Revenue of $134.2 Million, a 12% YoY Increase 3Q 2025 GAAP Net Income of $36.4 Million, a 1% YoY Increase 3Q 2025 Adjusted EBITDA(1) of $58.7</description>
</item>
<item>
<title>ADMA Biologics to Report Third Quarter 2025 Financial Results on November 5, 2025</title>
<link>https://6ix.com/company/adma-biologics-inc/news/adma-biologics-report-third-quarter-2025-financial-results-november-5-2025-2025-10-29</link>
<guid isPermaLink="true">https://6ix.com/company/adma-biologics-inc/news/adma-biologics-report-third-quarter-2025-financial-results-november-5-2025-2025-10-29</guid>
<pubDate>Wed, 29 Oct 2025 04:00:00 GMT</pubDate>
<description>Conference Call Scheduled for November 5, 2025, at 4:30 p.m. ET RAMSEY, N.J. and BOCA RATON, Fla., Oct. 29, 2025 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc.</description>
</item>
<item>
<title>ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/adma-biologics-inc/news/adma-biologics-announces-second-quarter-2025-financial-results-and-provides-business</link>
<guid isPermaLink="true">https://6ix.com/company/adma-biologics-inc/news/adma-biologics-announces-second-quarter-2025-financial-results-and-provides-business</guid>
<pubDate>Wed, 06 Aug 2025 04:00:00 GMT</pubDate>
<description>2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2</description>
</item>
<item>
<title>ADMA Biologics to Report Second Quarter 2025 Financial Results on August 6, 2025</title>
<link>https://6ix.com/company/adma-biologics-inc/news/adma-biologics-report-second-quarter-2025-financial-results-august-6-2025-2025-07-30</link>
<guid isPermaLink="true">https://6ix.com/company/adma-biologics-inc/news/adma-biologics-report-second-quarter-2025-financial-results-august-6-2025-2025-07-30</guid>
<pubDate>Wed, 30 Jul 2025 04:00:00 GMT</pubDate>
<description>Conference Call Scheduled for August 6, 2025, at 4:30 p.m. ET RAMSEY, N.J. and BOCA RATON, Fla., July 30, 2025 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc.</description>
</item>
<item>
<title>ADMA Biologics Announces First Quarter 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/adma-biologics-inc/news/adma-biologics-announces-first-quarter-2025-financial-results-and-provides-business</link>
<guid isPermaLink="true">https://6ix.com/company/adma-biologics-inc/news/adma-biologics-announces-first-quarter-2025-financial-results-and-provides-business</guid>
<pubDate>Wed, 07 May 2025 04:00:00 GMT</pubDate>
<description>1Q 2025 Total Revenue of $114.8 Million (Adjusted Total Revenue(1) of $118.6 Million), a 40% YoY Increase 1Q 2025 GAAP Net Income of $26.9 Million, a 51% YoY</description>
</item>
<item>
<title>ADMA Biologics to Report First Quarter 2025 Financial Results on May 7, 2025</title>
<link>https://6ix.com/company/adma-biologics-inc/news/adma-biologics-report-first-quarter-2025-financial-results-may-7-2025-2025-04-30</link>
<guid isPermaLink="true">https://6ix.com/company/adma-biologics-inc/news/adma-biologics-report-first-quarter-2025-financial-results-may-7-2025-2025-04-30</guid>
<pubDate>Wed, 30 Apr 2025 04:00:00 GMT</pubDate>
<description>Conference Call Scheduled for May 7, 2025, at 4:30 p.m. ET RAMSEY, N.J. and BOCA RATON, Fla., April 30, 2025 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq:</description>
</item>
<item>
<title>ADMA Biologics Announces U.S. FDA Approval of Innovative Production Yield Enhancement Process</title>
<link>https://6ix.com/company/adma-biologics-inc/news/adma-biologics-announces-us-fda-approval-innovative-production-yield-enhancement</link>
<guid isPermaLink="true">https://6ix.com/company/adma-biologics-inc/news/adma-biologics-announces-us-fda-approval-innovative-production-yield-enhancement</guid>
<pubDate>Mon, 28 Apr 2025 04:00:00 GMT</pubDate>
<description>Approval Supports Revenue Growth and Margin Expansion Opportunity, and Substantially Increases Peak Production Output Capacity First U.S. Regulatory Approval</description>
</item>
<item>
<title>ADMA Biologics Statement on Tariffs</title>
<link>https://6ix.com/company/adma-biologics-inc/news/adma-biologics-statement-tariffs-2025-04-07</link>
<guid isPermaLink="true">https://6ix.com/company/adma-biologics-inc/news/adma-biologics-statement-tariffs-2025-04-07</guid>
<pubDate>Mon, 07 Apr 2025 04:00:00 GMT</pubDate>
<description>Reiterates Strategic Advantage Through Fully U.S.-Based Manufacturing Operations, Commercialization and End-Market Sales, and Vertically Integrated U.S.-Based</description>
</item>
<item>
<title>ADMA Biologics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/adma-biologics-inc/news/adma-biologics-announces-fourth-quarter-and-full-year-2024-financial-results-and</link>
<guid isPermaLink="true">https://6ix.com/company/adma-biologics-inc/news/adma-biologics-announces-fourth-quarter-and-full-year-2024-financial-results-and</guid>
<pubDate>Mon, 03 Mar 2025 05:00:00 GMT</pubDate>
<description>FY 2024 Total Revenue of $426.5 Million, a 65% YoY Increase FY 2024 GAAP Net Income of $197.7 Million, Including an $84.3 Million Valuation Allowance Tax</description>
</item>
<item>
<title>ADMA Biologics to Participate in the Raymond James Institutional Investor Conference</title>
<link>https://6ix.com/company/adma-biologics-inc/news/adma-biologics-participate-raymond-james-institutional-investor-conference-2025-02-28</link>
<guid isPermaLink="true">https://6ix.com/company/adma-biologics-inc/news/adma-biologics-participate-raymond-james-institutional-investor-conference-2025-02-28</guid>
<pubDate>Fri, 28 Feb 2025 05:00:00 GMT</pubDate>
<description>RAMSEY, N.J. and BOCA RATON, Fla., Feb. 28, 2025 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial</description>
</item>
<item>
<title>ADMA Biologics to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025</title>
<link>https://6ix.com/company/adma-biologics-inc/news/adma-biologics-report-fourth-quarter-and-full-year-2024-financial-results-march-3</link>
<guid isPermaLink="true">https://6ix.com/company/adma-biologics-inc/news/adma-biologics-report-fourth-quarter-and-full-year-2024-financial-results-march-3</guid>
<pubDate>Tue, 25 Feb 2025 05:00:00 GMT</pubDate>
<description>Conference Call Scheduled for March 3, 2025, at 4:30 p.m. ET RAMSEY, N.J. and BOCA RATON, Fla., Feb. 25, 2025 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc.</description>
</item>
<item>
<title>ADMA Biologics Announces Preliminary Full Year 2024 Revenue and Provides Business Update</title>
<link>https://6ix.com/company/adma-biologics-inc/news/adma-biologics-announces-preliminary-full-year-2024-revenue-and-provides-business</link>
<guid isPermaLink="true">https://6ix.com/company/adma-biologics-inc/news/adma-biologics-announces-preliminary-full-year-2024-revenue-and-provides-business</guid>
<pubDate>Mon, 13 Jan 2025 05:00:00 GMT</pubDate>
<description>FY 2024 Preliminary Unaudited Total Revenue of Approximately $417-425 Million, Exceeding Previous Guidance of $415 Million YE 2024 Total Cash Grew to More</description>
</item>
</channel>
</rss>